SIG
34
-6
M
23
-4
DHI
28
-4
ZTS
6
-10
GIS
34
-3
BK
52
-8
ETR
52
-2
DOV
68
13
AMAT
33
-10
UAL
47
-14
GWW
50
-3
CMI
39
-7
RL
49
-10
VZ
39
-3
RHI
17
-6
HIG
60
-3
PVH
28
-6
UPS
14
-5
EFX
47
-7
NAVI
22
-7
SIG
34
-6
M
23
-4
DHI
28
-4
ZTS
6
-10
GIS
34
-3
BK
52
-8
ETR
52
-2
DOV
68
13
AMAT
33
-10
UAL
47
-14
GWW
50
-3
CMI
39
-7
RL
49
-10
VZ
39
-3
RHI
17
-6
HIG
60
-3
PVH
28
-6
UPS
14
-5
EFX
47
-7
NAVI
22
-7
Financhill
Back

Range Cancer Therapeutics ETF Stock Predictions

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
13

CNCR
Range Cancer Therapeutics ETF

Last Price:
$8.74
Seasonality Move:
1.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Crowdfunding to IPO: Nasdaq's Next Breakout?

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Range Cancer Therapeutics ETF Stock Forecast

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 3.6% based on the past 9 years of stock performance.
  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%
  • Is Range Cancer Therapeutics ETF Stock Undervalued?
    The current Range Cancer Therapeutics ETF [CNCR] share price is $8.40. The Score for CNCR is 13, which is 74% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Range Cancer Therapeutics ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 3.6% based on the past 9 years of stock performance.

Range Cancer Therapeutics ETF Stock Rating

Sell
13
Range Cancer Therapeutics ETF (CNCR) is a Sell

Is Range Cancer Therapeutics ETF overpriced?

  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%

Range Cancer Therapeutics ETF Stock Price History

Is CNCR stock going to rise?

  • The current trend is moderately bullish and CNCR is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
16.27
52-Week Low:
7.88

Prediction Charts

Market Cap:
0
Price in USD:
8.40
Volume:
1.9K
Beta:
1.15

Technical Analysis

SMA50:
11.00
SMA100:
12.04
SMA200:
13.39
52-Wk Change:
-45.98%

Stock Predictions

  • Is Range Cancer Therapeutics ETF stock public?
    Yes, Range Cancer Therapeutics ETF is a publicly traded company.
  • What is the Range Cancer Therapeutics ETF stock quote today?
    The Range Cancer Therapeutics ETF stock price is 8.40 USD today.
  • How to buy Range Cancer Therapeutics ETF stock online?
    You can buy Range Cancer Therapeutics ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-24 10.87 10.83 10.88 10.83
Mar-25 10.50 10.50 10.50 10.50
Mar-26 10.48 10.10 10.48 10.06
Mar-27 10.15 10.04 10.15 10.04
Mar-28 9.87 9.87 9.87 9.87
Mar-31 9.68 9.43 9.68 9.37
Apr-1 9.41 9.00 9.41 9.00
Apr-2 8.97 9.38 9.38 8.97
Apr-3 8.92 8.92 8.97 8.84
Apr-4 8.40 8.42 8.62 8.40
Apr-7 8.05 8.46 8.59 7.88
Apr-8 8.57 8.01 8.58 8.01
Apr-9 7.94 8.69 8.75 7.94
Apr-10 8.16 8.40 8.40 8.09

Range Cancer Therapeutics ETF Earnings

Data Unavailable

Range Cancer Therapeutics ETF Forecast Revenue Growth

Data Unavailable

* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.